AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

OTCMKTS:DMCAFDiaMedica Therapeutics Stock Price, Forecast & News

$7.10
-0.05 (-0.70 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.10
Now: $7.10
$7.33
50-Day Range
$2.61
MA: $5.05
$7.32
52-Week Range
$0.19
Now: $7.10
$0.69
Volume54,100 shs
Average Volume131,151 shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.02
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DMCAF
CUSIPN/A
CIKN/A
Phone763-496-5454

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.12 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive DMCAF News and Ratings via Email

Sign-up to receive the latest news and ratings for DMCAF and its competitors with MarketBeat's FREE daily newsletter.

DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions

Has DiaMedica Therapeutics been receiving favorable news coverage?

Media stories about DMCAF stock have been trending negative on Tuesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about DiaMedica Therapeutics.

Who are some of DiaMedica Therapeutics' key competitors?

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
  • Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
  • Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMCAF stock can currently be purchased for approximately $7.10.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $1.12 billion.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.